Gilead (GILD) Stock Advancing on Credit Suisse Note
NEW YORK (TheStreet) -- Shares of Gilead Sciences (GILD) - Get Report are up 0.56% to $86.74 today after analysts at Credit Suisse released a note favoring the stock.
The firm said that the stock is trading as if the company's pipeline has very little worth. This is due to recent "weakness" in the biotech market.
Credit Suisse analysts said that much of the debate surrounding the stock is about whether or not the company will do deals to enhance its product line. Credit Suisse added that analysts at other firms are giving the company's pipeline "little credit."
However, Gilead is strong in the hepatitis-C business. Credit Suisse estimates Gilead's 2022 HCV sales at $11.5 billion vs. consensus estimates of $10.6 billion.
Gilead Sciences is a Foster City, CA-based research and biopharmaceuticals company.
Separately, TheStreet Ratings rated this stock as a "buy" with a ratings score of B.
The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels and expanding profit margins. TheStreet Ratings feels its strengths outweigh the fact that the company has had sub par growth in net income.
You can view the full analysis from the report here: GILD
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.